Together with Willkie Farr & Gallagher, the healthcare boutique NOVACOS advised the financial investor Ardian on the sale of the international pharmaceutical company RIEMSER, which was also reported in the renowned magazine JUVE. NOVACOS was responsible for aspects of pharmaceutical law and compliance in the transaction. The closing of the transaction is still pending.
ESTEVE announced on 8 January 2020 that they have come to an agreement to acquire all the shares of the German pharmaceutical company RIEMSER from Ardian, a world-leading private investment house.
Headquartered in Berlin, RIEMSER has a diversified portfolio of products with the 3 main therapeutic areas being: oncology, neurology and niche therapies. RIEMSER operates a pharmaceutical manufacturing plant in Germany and has direct geographical presence in four of Europe’s five major countries: Germany, United Kingdom, France, and Spain. Over 80% of sales come from the hospital channel, providing specialty treatments and a wide range of pharmaceuticals in therapeutic niche areas.
ESTEVE’s purchase of RIEMSER will accelerate its transformation into a specialty pharma company with more than 60% of its sales coming from proprietary products; it will also give ESTEVE access to a high-growth sector – the hospital market.
As a law firm specializing in healthcare M&A transactions, NOVACOS advised on the complex regulatory requirements in the pharmaceutical sector, which play a significant role in M&A transactions in this field. The following NOVACOS team was involved: Christian Hübner (lead partner), Dr. Christian Stallberg, Dr. Marc Oeben, Maria Heil; Associates: Jonathan Baruth, Catarina Seemann (all regulatory/healthcare). NOVACOS advised on the transaction alongside Willkie Farr & Gallagher as lead law firm.
You can find the press coverage by JUVE under this link.